Inhibitory effect of triptolide on interleukin-18 and its receptor in rheumatoid arthritis synovial fibroblasts

Inflammation Research

Volumn 57, Issue 6, 2008, Pages 260-265

  Lu, Y ^a   Wang, W J ^b   Leng, J H ^c   Cheng, L F ^a   Feng, L ^a   Yao, H P ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Interleukin 18; Interleukin 18 receptor; Rheumatoid arthritis; Synovial fibroblasts; Triptolide

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; PHORBOL 13 ACETATE 12 MYRISTATE; TRIPTOLIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DITERPENES; EPOXY COMPOUNDS; FIBROBLASTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-18; PHENANTHRENES; RECEPTORS, INTERLEUKIN-18; SYNOVIAL MEMBRANE; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR RELA;

EID: 46449120567     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-7128-9     Document Type: Article

References (33)

1. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 1996, 39: 1781-90.
2. Kim WU, Kwok SK, Hong KH, Yoo SA, Kong JS, Choe J, Cho CS. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther. 2007, 9(2): R42
3. Sivalingam SP, Thumboo J, Vasoo S, Thio ST, Tse C, Fong KY. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singapore. 2007, 36(2): 96-9.
4. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis. 2003, 62 (Suppl 2): ii60-7.
5. Lin N, Liu C, Xiao C, Jia H, Imada K, Wu H, Ito A. Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol. 2007 , 1; 73(1): 136-46.
6. Wang B, Ma L, Tao X, Lipsky PE. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum. 2004 ,50(9): 2995-303.
7. Dinarello CA. Interleukin-18. Methods. 1999,19(1):121-32.
8. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M. Cloning of the cDNA for human IFN-γ-inducing factor , expression in Escherichia coli , and studies on the biologic activities of the protein. J Immunol, 1996, 156: 4274-9
9. Dai SM, Nishioka K, Yudoh K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis. 2004 , 63(11): 1379-86.
10. Kawashima M, Miossec P. Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis. Arthritis Res Ther. 2004, 6(1): R39-R45.
11. Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, Spadaro A, Valesini G. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis. 2002 , 61(8): 723-5.
12. Dai SM, Shan ZZ Dr, Xu H, Nishioka K. Cellular targets of Interleukin-18 in rheumatoid arthritis. Ann Rheum Dis. 2007 May 14; [Epub ahead of print]
13. Cho ML, Jung YO, Moon YM, Min SY, Yoon CH, Lee SH, Park SH, Cho CS, Jue DM, Kim HY. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett. 2006, 103(2): 159-66.
14. Yao H, Zhou J, Li D, Wu N, Bader A, Hoxtermann S, Altmeyer P, Brockmeyer NH. FK506 enhances triptolide-induced down-regulation of cyclooxygenase-2, inducible nitric oxide synthase as well as their products PGE2 and NO in TNF-alpha-stimulated synovial fibroblasts from rheumatoid arthritic patients. Eur J Med Res. 2005; 10(3): 110-6.
15. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001, 44(2): 275-85.
16. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum. 1998 , 41(1): 130-8
17. Liu CF, Lin N. Progress in research on mechanisms of anti-rheumatoid arthritis of triptolide. Zhongguo Zhong Yao Za Zhi. 2006 , 31(19): 1575-9.
18. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin lnvest ,1999, 104: 1393-1401.
19. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T, Sanou O, Kojima H, Fujii M, Ohta T, Ikeda M, Ikegami H, Kurimoto M. Purification and characterization of the human interleukin-18 receptor. J Biol chem, 1997; 272(41): 25737-42
20. Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 2001, 42(3): 253-65.
21. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthiritis Rheum, 2001, 44: 275-85.
22. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 2001, 167: 1644-53.
23. Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, Kanamaru A. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol. 2004, 173(8): 5312-8.
24. Jingwu Zhang. Yin and yang interplay of IFN-γ in inflammation and autoimmune disease. J Clin Invest. 2007, 117(4): 871-3
25. Han Z, Boyle DL, Manning AM, Firestein GS. AP-l and NF-KappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity, 1998, 28(4): 197-208
26. Jue DM, Jeon KI, Jeong JY. Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. J Korean Med Sci. 1999, 14(3): 231-8.
27. Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M, Ohta T, Kurimoto M. Interleukin-18 activates NF-κB in murine T helper type 1 cells. Biochem Biophys Res Commun, 1997, 234(2): 454-7.
28. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 2007, 56(6): 1787-97.
29. Sylvester J, Liacini A, Li WQ, Dehnade F, Zafarullah M. Tripterygium wilfontii Hok F extract suppresses proinflammatory Cytokine-induced expression of matrix metallopmteinase genes in articular chondrocytes by inhibiting activating protein-l and nuclear factor-KappaB activities. Mol Pharmacol, 2001,59(5): 1196-1205
30. Holmes S, Abrahamson JA, Al-Mahdi N, Abdel-Meguid SS, Ho YS. Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18. Hybridoma, 2000, 19(5): 363-7
31. Dinarello CA. Targeting interleukin-18 with interleukin-18 binding protein. Ann Rheum Dis, 2000, 59 (Suppl 1): i17-20
32. Bresnihan B, Roux-Lombard P, Murphy E, Kane D, FitzGerald O, Dayer JM. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis, 2002; 61: 726-9.
33. Iain B McInnes, Foo Y Liew and J Alastair Gracie. Interleukin-18: a therapeutic target in rheumatoid arthritis? Arthritis Res Ther, 2005, 7: 38-41